Antifungal prophylaxis for very low birthweight infants: UK national survey
- 1Ninewells Hospital and Medical School, Dundee, Scotland
- 2Australian National University, Canberra, Australia
- W McGuire, Centre for Newborn Care, Canberra Hospital, ACT 2606, Australia; william.mcguire{at}act.gov.au
- Accepted 8 August 2007
- Published Online First 3 September 2007
Abstract
In a UK-wide survey, 28% of neonatal units reported using systemic or topical/oral antifungal prophylaxis for very low birthweight infants. Systemic prophylaxis is targeted to extremely preterm infants with additional risk factors for invasive fungal infection. Currently, there seems to be sufficient variation in practice to undertake randomised trials of these interventions.
Footnotes
-
Competing interests: The authors have previously received an educational grant from Pfizer UK Ltd, a manufacturer of fluconazole. This company had no role in the collection, analysis and interpretation of data, or in the writing of the report or decision to submit for publication.
